New trivalent vaccine for clade 1 sarbecoviruses
The vaccine provided complete protection with no detectable virus in the lungs and could be a routine part of people’s medical treatment.
List view / Grid view
The vaccine provided complete protection with no detectable virus in the lungs and could be a routine part of people’s medical treatment.
The study's findings could be applied to the development of new vaccine and therapeutic strategies for influenza.
A new vaccine, based on a nanoliposome that promotes proteins to be displayed on its surface, results in potent vaccine efficacy.
The interactions linking intestinal microbiota with the functionality of basally resident alveolar macrophages and severity of infection are revealed.
The new antibodies can neutralise certain H1 and H3 strains with or without the 133a insertion, which could lead to improved vaccines.
St. Jude Children’s Research Hospital, in collaboration with ESR Limited, discovered that specific immune cells present in individuals months before a flu infection can better predict symptom development compared to current antibody-based methods.
Researchers provide new insights into viral evolution and have significant implications for understanding and predicting the behaviour of influenza and other mutating diseases.
Australian researchers have tested a new nasal vaccine in mice, with the potential enhance protection against COVID-19.
H84T-BanLec has viral-blocking abilities by binding to polysaccharides that are present on the surface of the viruses.
Dr Christopher Locher, Versatope Therapeutics, explains why bacterial extracellular vesicles are ideally suited for recombinant vaccines because target antigens can be expressed as fusion proteins and targeted to the lumen, membrane or surface of the vesicles. These nano-size vesicles represent a potentially safe and simple subunit vaccine delivery platform that…
Janssen's monoclonal antibody CR9114, for the potential treatment of influenza, has been exclusively licensed by Leyden Labs for development and commercialisation.
Researchers have found a small subset of antibodies that target a site at the base of the influenza virus hemagglutinin protein.
The new nanoparticle adjuvant improved antibody production following vaccination against HIV, diphtheria and influenza in mouse models.
Antibodies produced by B cells against the H1N1 influenza virus can also neutralise other strains, which could be used to developed vaccines.
Using nanoparticle liposomes, researchers have developed an experimental flu vaccine that has shown success in pre-clinical studies.